Skip to main content

Advertisement

Table 3 Overview of published clinical trial studies of epigenetic drugs in MM

From: Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma

Epigenetic function Compound Phase Reference
BET inhibitor OTX015/MK-8628 I [158]
BET inhibitor CPI-0610 I [159]
BET inhibitor GSK525762 I/II [159]
DNMT/HDAC inhibitor Azacitidine/phenylbutyrate III [159]
HDAC inhibitor Abexinostat I [159]
HDAC inhibitor Belinostat II [159]
HDAC inhibitor CI-994 II [159]
HDAC inhibitor CUDC-907 I [159]
HDAC inhibitor Entinostat I [159]
HDAC inhibitor ITF2357 II [159]
HDAC inhibitor Panobinostat II [159]
HDAC inhibitor Panobinostat in combination with bortezomib and dexamethasone FDA approved [146, 159]
HDAC inhibitor Panobinostat in combination with everolimus I/II [159]
HDAC inhibitor Rocilinostat I/II [159]
HDAC inhibitor Tefinostat I [159]
HDAC inhibitor Valproate I [159]
HDAC inhibitor Vorinostat I/II [159]
HAT inhibitor Curcumin Preliminary clinical study [160]